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Midlife type 2 diabetes and poor glycaemic control as risk 
factors for cognitive decline in early old age: a post-hoc 
analysis of the Whitehall II cohort study
Richard H Tuligenga, Aline Dugravot, Adam G Tabák, Alexis Elbaz, Eric J Brunner, Mika Kivimäki, Archana Singh-Manoux
Summary
Background Type 2 diabetes increases the risk for dementia, but whether it aﬀ ects cognition before old age is unclear. 
We investigated whether duration of diabetes in late midlife and poor glycaemic control were associated with 
accelerated cognitive decline.
Methods 5653 participants from the Whitehall II cohort study (median age 54·4 years [IQR 50·3–60·3] at ﬁ rst 
cognitive assessment), were classiﬁ ed into four groups: normoglycaemia, prediabetes, newly diagnosed diabetes, and 
known diabetes. Tests of memory, reasoning, phonemic and semantic ﬂ uency, and a global score that combined all 
cognitive tests, were assessed three times over 10 years (1997–99, 2002–04, and 2007–09). Mean HbA1c was used to 
assess glycaemic control during follow-up. Analyses were adjusted for sociodemographic characteristics, health-
related behaviours, and chronic diseases.
Findings Compared with normoglycaemic participants, those with known diabetes had a 45% faster decline in 
memory (10 year diﬀ erence in decline –0·13 SD, 95% CI –0·26 to –0·00; p=0·046), a 29% faster decline in reasoning 
(–0·10 SD, –0·19 to –0·01; p=0·026), and a 24% faster decline in the global cognitive score (–0·11 SD, –0·21 to –0·02; 
p=0·014). Participants with prediabetes or newly diagnosed diabetes had similar rates of decline to those with 
normoglycaemia. Poorer glycaemic control in participants with known diabetes was associated with a signiﬁ cantly 
faster decline in memory (–0·12 [–0·22 to –0·01]; p=0·034) and a decline in reasoning that approached signiﬁ cance 
(–0·07 [–0·15 to 0·00]; p=0·052).
Interpretation The risk of accelerated cognitive decline in middle-aged patients with type 2 diabetes is dependent on 
both disease duration and glycaemic control.
Funding US National Institutes of Health, UK Medical Research Council.
Introduction
Dementia represents a serious public health challenge 
because of ageing populations worldwide.1 The 
prevalence of type 2 diabetes is also rising rapidly around 
the world, and increases the risk of dementia, including 
Alzheimer’s disease.2–4 Several studies have shown poorer 
cognitive performance and faster cognitive decline in 
people with diabetes than in those without the 
disease.5–9 However, with some notable exceptions,5,7,9 most 
of the evidence for the eﬀ ect of type 2 diabetes on 
cognitive ageing comes from studies in elderly 
populations.6,8 Typically, such research is based on adults 
aged 65 years or older at the start of the study, with 
follow-up measurement of incident dementia. Some 
researchers believe that diabetes does not necessarily 
aﬀ ect cognition before old age,10,11 the implication being 
that the association between the two exists not because 
diabetes is a risk factor for dementia, but because of 
shared risk factors such as hypertension. Since dementia 
is a progressive disease involving cognitive decline over 
several years,12,13 investigation is needed to determine 
whether diabetes aﬀ ects cognitive decline before old age.
Our aim was to assess whether, compared with 
normoglycaemia, type 2 diabetes and prediabetes14 
are associated with faster cognitive decline from late 
midlife (age 55 years) to early old age (age 65 years), an age 
range in which dementia is uncommon. We also aimed to 
examine the possibility of a dose-response relation by 
investigating the role of duration of diabetes (the 
underlying hypothesis being that if diabetes is a risk factor 
for cognition then longer exposure to diabetes would have 
a stronger eﬀ ect on cognitive decline) and to investigate 
whether glycaemic control (measured by HbA1c), including 
among individuals with type 2 diabetes, is associated with 
cognitive decline.
Methods
Study design and participants
The Whitehall II study was established in 1985 with the 
recruitment of British civil servants aged 35–55 years 
from 20 London-based departments to investigate 
determinants of chronic diseases, with the baseline 
assessment taking place in 1985–88.15 Clinical 
examinations were also done in 1991–93, 1997–99, 
2002–04, and 2007–09. Cognitive testing was introduced 
to the study in 1997–99 and repeated in 2002–04 and 
2007–09. Written informed consent from participants and 
research ethics approvals (University College London 
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ethics committee) were renewed at each contact; the most 
recent approval was from the Joint University College 
London/University College London Hospital Committee 
on the Ethics of Human Research (Committee Alpha), 
reference number 85/0938.
Measurements
We ascertained type 2 diabetes status in 1991–93 and 
1997–99. We took venous blood samples after a 
minimum 5 h fast, followed by a 75 g, 2 h oral glucose 
tolerance test. Blood samples were drawn into ﬂ uoride 
monovette tubes and centrifuged on site. We measured 
blood glucose using the glucose oxidase 
method.16 Type 2 diabetes was deﬁ ned by WHO 
criteria,17 based on a fasting glucose of 7·0 mmol/L or 
more, or a 2 h postload glucose of 11·1 mmol/L or more. 
Participants who met these criteria at the 
1991–93 examination or who had known diabetes in 
1997–99 (ie, doctor-diagnosed diabetes or use of 
antidiabetic drugs) were classiﬁ ed as known diabetes. 
Those without a history of diabetes, but who met the 
diabetes criteria at the 1997–99 examination were 
classiﬁ ed as newly diagnosed diabetes. Non-diabetic 
participants were classiﬁ ed as prediabetic if their fasting 
plasma glucose concentration was between 6·1 and less 
than 7·0 mmol/L and their 2 h postload glucose 
concentration was less than 7·8 mmol/L (impaired 
fasting glucose), or if their fasting glucose was less than 
7·0 mmol/L and their 2 h postload plasma glucose 
concentration was between 7·8 and less than 
11·1 mmol/L (impaired glucose tolerance).17 Others were 
classiﬁ ed as normoglycaemic. 
Glycaemic control was characterised by HbA1c, which 
was measured in EDTA (edetic acid) whole blood on a 
calibrated high-performance liquid chromatography 
system with automated haemolysis before injection. We 
used mean values from 2002–04 and 2007–09 measure-
ments to represent glycaemic control during follow-up.
We used a comprehensive battery of cognitive tests 
appropriate for middle-aged individuals.18 Short-term 
verbal memory was tested with a 20-word free-recall 
test in which participants were presented a list of 
20 one-syllable or two-syllable words at intervals of 2 s 
and were asked to recall in writing as many of the words 
as possible, in any order, in 2 min. We used the Alice 
Heim 4-I test19 to assess inductive reasoning, measuring 
the ability of participants to identify patterns and infer 
principles and rules. This test consists of a series of 
65 verbal and mathematical reasoning items of 
increasing diﬃ  culty; participants had 10 min to do the 
test. Verbal ﬂ uency was assessed with tests of phonemic 
ﬂ uency (words beginning with s) and semantic ﬂ uency 
(animal names),20 with 1 min allowed for each test. We 
standardised the results of the four tests to Z scores 
using the mean and SD from the 1997–99 assessments, 
and averaged them to create a global cognitive score. 
The global cognitive score was then re-standardised so 
that the mean was 0 and the SD was 1. Previous 
research has used global scores constructed in this way 
to minimise problems caused by measurement error in 
the individual tests21 and to allow comparison of 
ﬁ ndings across studies when eﬀ ects are not limited to 
one cognitive domain. For all cognitive tests, including 
the global score, we used standardised values in the 
regression analysis to allow comparison of beta 
coeﬃ  cients between results for the diﬀ erent tests.
Covariates included sociodemographic characteristics, 
health-related behaviours, and chronic diseases. 
Sociodemographic characteristics were age, sex, marital 
status (single, divorced, widowed, married, or 
cohabiting) and education (low [did not complete 
secondary school], middle [secondary school], and high 
[university degree or higher]). Health-related behaviours 
were smoking (current smoker, ex-smoker, or never 
smoked), alcohol consumption per week (abstainer [zero 
units], moderate drinker [one to 21 units for men, one to 
14 units for women], or heavy drinker [more than 
21 units for men, more than 14 units for women]), 
adequate physical activity (yes or no; as per WHO 
recommendations,22 assessed via a 20-item question-
naire); and frequency of fruit and vegetable consumption 
(less than once daily, once daily, or more frequently). 
Chronic disease covariates (based on self-report of doctor 
diagnosis and corroborated in medical records) were 
coronary heart disease, stroke, hypertension (deﬁ ned as 
blood pressure of 140/90 mm Hg or higher, or use of 
antihypertensive drugs), respiratory disease, total 
cholesterol, obesity (BMI of 30 kg/m² or greater), use of 
antidepressants, and use of lipid-lowering drugs. Figure: Study proﬁ le
1991–93
n=8637 (aged 39–64 years)
• Diabetes screening
Cross-sectional analyses
n=5183 
1997–99
n=7870 (aged 45–69 years)
• Diabetes screening
• First cognitive assessment
2687 excluded
               502 were non-white participants
            1428 had data missing for diabetes status
               156 had data missing for covariates
               601 had missing data for cognitive function
2002–04
n=6967 (aged 50–74 years) 
• Diabetes screening, HbA1c measurement
• Second cognitive assessment
Longitudinal analysis
n=5653
2007–09
n=6761 (aged 55–79 years)
• Diabetes screening, HbA1c measurement
• Third cognitive assessment
 2217 excluded
               502 were non-white participants
            1428 had data missing for diabetes status
               156 had data missing for covariates
               131 had missing data for cognitive function
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Statistical analysis
We examined associations between baseline characteristics 
and diabetes status using χ² squared tests (categorical 
data) and analysis of variance (continuous data). We did 
cross-sectional analyses for diabetes status and cognitive 
measures from 1997–99 using linear regression. We used 
three sets of adjustments with measures from 1997–99: 
model 1 was adjusted for sociodemographic measures 
only; model 2 also included health-related behaviours; and 
model 3 also included chronic diseases.
For longitudinal analyses, we used linear mixed models 
to examine the association of diabetes status in 
1997–99 with cognitive decline over 10 years (1997–99, 
2002–04, and 2007–09). In these models, ﬁ xed eﬀ ects 
were terms for time, main eﬀ ect terms for diabetes status 
and all covariates (main eﬀ ects for covariates allow for 
adjustment of their cross-sectional eﬀ ect on cognitive 
function), and interactions between time and all variables 
in the model. The interaction between a variable and 
time represents its eﬀ ect on cognitive decline, and 
inclusion of interactions with time for all covariates 
allows the estimation of diabetes and cognitive decline to 
be adjusted for the eﬀ ect of all covariates on cognitive 
decline. Both the intercept and the slope were ﬁ tted as 
random eﬀ ects, allowing individuals to have diﬀ erent 
cognitive scores at baseline and diﬀ erent rates of 
cognitive decline during follow-up.
Age was centred at the median on the basis of the 
1997–99 assessment and used as the timescale in the 
longitudinal analyses. This term was divided by ten; 
thus, the coeﬃ  cient associated with unit change in time 
represents cognitive decline over 10 years to match the 
10 year follow-up. These analyses were also adjusted for 
age at the start of the cognitive follow-up and included 
covariates from 1997–99 across the three models, as in 
the cross-sectional analyses. The normoglycaemia group 
was used as the reference group to calculate diﬀ erences 
in cognitive decline in the prediabetes and diabetes 
groups.
To allow interpretation of the cross-sectional and 
longitudinal estimates, we compared them with the 
eﬀ ect of age on cognition by dividing the estimate by the 
eﬀ ect of a 1 year increase in age on cognition. We 
calculated the eﬀ ect of age by regression of the 
standardised 1997–99 cognitive score on age.
In the ﬁ nal analyses, we examined whether poorer 
glycaemic control, modelled as a one percentage point 
increment in HbA1c, was associated with cognitive 
decline in participants with normoglycaemia, 
prediabetes, newly diagnosed diabetes, or known 
diabetes. The normal distribution of the HbA1c measure 
allowed the use of a one percentage point increment as 
the exposure in these analyses, which were done by use 
of linear mixed models with an interaction term between 
diabetes status, HbA1c, and time of follow-up to estimate 
cognitive decline associated with a one percentage point 
increase in HbA1c.
Non-white participants (n=502) were excluded from the 
main analyses because a test of interaction showed the 
association of diabetes with cognition to diﬀ er in this 
subgroup (p=0·0013 for the global cognitive score), and 
small numbers precluded further analyses. However, to 
Normoglycaemia 
(n=4703)
Prediabetes* 
(n=648)
Newly diagnosed 
diabetes (n=115)
Known diabetes 
(n=187)
p value
Age (years) 55·1 (5·9) 57·5 (6·1) 59·0 (6·1) 57·4 (6·3) <0·0001
Men 3428 (73%) 474 (73%) 81 (70%) 130 (70%) 0·71
Single, divorced, or widowed 1106 (24%) 146 (23%) 32 (28%) 47 (25%) 0·61
Low education 2018 (43%) 292 (45%) 56 (49%) 93 (50%) 0·14
Heavy alcohol consumption† 1270 (27%) 195 (30%) 26 (23%) 52 (28%) 0·26
Current smoker 482 (10%) 48 (7%) 12 (10%) 14 (7%) 0·10
Inadequate physical activity‡ 3522 (75%) 477 (74%) 92 (80%) 153 (82%) 0·08
Fruit and vegetable intake less than once daily 1218 (26%) 144 (22%) 27 (23%) 41 (22%) 0·14
Respiratory illness 351 (7%) 43 (7%) 6 (5%) 20 (11%) 0·23
Total cholesterol (mmol/L) 5·91 (1·05) 6·12 (1·06) 6·12 (1·12) 5·92 (1·03) <0·0001
Obesity (BMI ≥30 kg/m²) 561 (12%) 124 (19%) 20 (17%) 43 (23%) <0·0001
Hypertension 1134 (24%) 257 (40%) 53 (46%) 88 (47%) <0·0001
Stroke 14 (<1%) 1 (<1%) 1 (1%) 2 (1%) 0·17
Coronary heart disease 240 (5%) 44 (7%) 14 (12%) 21 (11%) <0·0001
Use of antidepressant drugs 129 (3%) 12 (2%) 5 (4%) 5 (3%) 0·39
Use of lipid-lowering drugs 122 (3%) 22 (3%) 9 (8%) 14 (7%) <0·0001
Data are n (%) or mean (SD). *Prediabetes was deﬁ ned with a 75 g oral glucose tolerance test as one of two states: impaired fasting glucose, deﬁ ned as fasting plasma glucose 
between 6·1 mmol/L and less than 7·0 mmol/L, without impaired glucose tolerance; or impaired glucose tolerance, deﬁ ned as fasting glucose of less than 7·0 mmol/L and a 
2 h postload plasma glucose concentration between 7·8 mmol/L and less than 11·1 mmol/L. †More than 21 units per week for men and more than 14 units per week for 
women. ‡Less than WHO recommendations.22
 Table 1: Characteristics of the study population, by diabetes status in 1997–99
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allow comparison, we examined cognitive decline as a 
function of diabetes status (yes or no) in these 
participants. We also did sensitivity analyses to assess the 
robustness of our main ﬁ ndings. These were: replacing 
the hypertension measure in model 3 with systolic and 
diastolic blood pressure as continuous variables; 
removing from the analysis all participants who became 
diabetic after the clinical examination in 1997–99, based 
on clinical assessments in 2002–04 and 2007–09; using 
an alternative classiﬁ cation of diabetes status in which 
newly diagnosed diabetes and known diabetes were 
replaced with diabetes diagnosis 0–1·5 years ago and 
diabetes diagnosis more than 1·5 years ago, respectively, 
on the basis of age at diagnosis of diabetes and age at the 
1997–99 clinical assessment; using all covariates as time-
dependent variables; and using a multiple imputation, 
chained-equations method to replace missing data for 
cognition and covariates during follow-up, using all 
available data for exposures, outcomes, and covariates in 
the analysis. All analyses were done in Stata SE version 
12 for Windows (StataCorp, 2011). p values were two 
sided and p<0·05 was regarded as signiﬁ cant.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Of the 10 308 participants recruited at the beginning of 
the study in 1985–88, 8637 (84%) attended the diabetes 
screening in 1991–93, and 7870 (76%) attended in 
1997–99 when the ﬁ rst cognitive assessment took place 
(ﬁ gure). The median age of participants was 54·4 years 
(IQR 50·3–60·3) in 1997–99, 59·9 years (55·8–65·7) in 
2002–04, and 64·7 years (60·8–70·6) in 2007–09. No 
diﬀ erences in sex (interaction p=0·15–0·97) or age 
(interaction p=0·39–0·77) were noted in associations of 
diabetes with cognitive decline, leading us to combine 
men and women and all age groups in the analyses and 
to adjust the models for age and sex.
Table 1 shows the characteristics of the study population 
by diabetes status in 1997–99. The mean duration of 
diabetes in participants with known diabetes was 4·95 
(SD 2·21) years. Of the 5653 people included in the 
longitudinal analyses, 4073 (72%) had cognitive data 
recorded at all three assessments, 1000 (18%) at two 
assessments, and 580 (10%) at one assessment. 
Compared with individuals not included in the 
longitudinal analyses, the samples consisted of younger 
participants (mean age 55·5 vs 57·1 years, p<0·0001), 
and contained more men (4113 [73%] of 5653 vs 1360 
[61%] of 2217, p<0·0001), and more educated individuals 
(1678 [30%] of 5653 vs 542 [24%] of 2217 with a university 
degree, p<0·0001). 
Age was inversely associated with cognition; a 1 year 
increase in age was associated with a –0·039 SD (95% CI 
–0·043 to –0·035) decrement in memory, a –0·035 SD 
(–0·039 to –0·030) decrement in reasoning, a –0·036 SD 
(–0·041 to –0·032) decrement in phonemic ﬂ uency, a 
–0·040 SD (–0·044 to –0·035) decrement in semantic 
ﬂ uency, and a –0·050 SD (–0·054 to –0·046) decrement 
in global cognitive score (all p<0·0001).
Cross-sectional analyses were based on 5183 people 
with complete cognitive data in 1997–99; 606 (12%) had 
prediabetes, 110 (2%) had newly diagnosed diabetes, and 
146 (3%) had known diabetes. Compared with 
normoglycaemic individuals, those with known diabetes 
had a –0·16 SD (95% CI –0·30 to –0·02) lower score in 
reasoning in the fully adjusted model (model 3; p=0·023; 
table 2), although the results for the other cognitive 
measures (including global cognitive score) were not 
signiﬁ cant. The coeﬃ  cient from model 3 in individuals 
with known diabetes corresponds to an age eﬀ ect of 
roughly 4·6 years for reasoning.
Model 1 Model 2 Model 3
Memory
Normoglycaemia ·· ·· ··
Prediabetes –0·05 (–0·13 to 0·03) –0·05 (–0·13 to 0·03) –0·04 (–0·13 to 0·04)
Newly diagnosed diabetes –0·09 (–0·27 to 0·09) –0·08 (–0·26 to 0·10) –0·07 (–0·25 to 0·12)
Known diabetes 0·01 (–0·15 to 0·17) 0·02 (–0·14 to 0·17) 0·03 (–0·13 to 0·18)
Reasoning
Normoglycaemia ·· ·· ··
Prediabetes 0·03 (–0·04 to 0·10) 0·02 (–0·05 to 0·09) 0·03 (–0·04 to 0·10)
Newly diagnosed diabetes 0·05 (–0·12 to 0·21) 0·06 (–0·10 to 0·22) 0·07 (–0·09 to 0·23)
Known diabetes –0·19 (–0·33 to –0·05)* –0·18 (–0·32 to –0·04)† –0·16 (–0·30 to –0·02)‡
Phonemic ﬂ uency
Normoglycaemia ·· ·· ··
Prediabetes –0·05 (–0·13 to 0·03) –0·06 (–0·14 to 0·02) –0·05 (–0·13 to 0·03)
Newly diagnosed diabetes –0·03 (–0·21 to 0·15) –0·02 (–0·20 to 0·16) –0·01 (–0·18 to 0·17)
Known diabetes –0·07 (–0·23 to 0·08) –0·07 (–0·23 to 0·08) –0·05 (–0·21 to 0·10)
Semantic ﬂ uency
Normoglycaemia ·· ·· ··
Prediabetes –0·03 (–0·11 to 0·05) –0·03 (–0·11 to 0·05) –0·03 (–0·11 to 0·05)
Newly diagnosed diabetes –0·09 (–0·26 to 0·09) –0·08 (–0·25 to 0·10) –0·07 (–0·24 to 0·11)
Known diabetes –0·13 (–0·28 to 0·02) –0·12 (–0·27 to 0·03) –0·11 (–0·27 to 0·04)
Global score
Normoglycaemia ·· ·· ··
Prediabetes –0·03 (–0·11 to 0·04) –0·04 (–0·12 to 0·03) –0·03 (–0·11 to 0·04)
Newly diagnosed diabetes –0·05 (–0·22 to 0·11) –0·04 (–0·21 to 0·12) –0·02 (–0·19 to 0·14)
Known diabetes –0·13 (–0·28 to 0·01) –0·12 (–0·26 to 0·02) –0·10 (–0·25 to 0·04)
Data are beta coeﬃ  cients (95% CI) based on standardised cognitive scores (mean =0, SD=1). p values for signiﬁ cant 
results (p<0·05) compared with reference group are indicated by footnotes. Model 1 is adjusted for age, sex, marital 
status, and education. Model 2 is adjusted for same parameters as model 1 plus health-related behaviours (smoking, 
alcohol, physical activity, and fruit and vegetable consumption). Model 3 is adjusted for same parameters as model 2 
plus coronary heart disease, stroke, hypertension, respiratory disease, total cholesterol, obesity, use of antidepressants, 
and use of lipid-lowering drugs. n for normoglycaemia is 4321; n for prediabetes is 606; n for newly diagnosed 
diabetes is 110; and n for known diabetes is 146. *p=0·008. †p=0·011. ‡p=0·023.
Table 2: Estimated diﬀ erences in cognitive function, as a function of diabetes status (cross-sectional 
analysis at 1997–99 assessment)
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We initially did the longitudinal analyses using a 
simple binary classiﬁ cation of diabetes status in 1997–99: 
diabetic versus non-diabetic (normoglycaemia and 
prediabetes). These results (appendix p 1) show faster 
declines in reasoning, phonemic ﬂ uency, and the global 
cognitive score in participants with diabetes than in 
those without diabetes. The eﬀ ect sizes were larger, albeit 
with wide CIs, in non-white participants (appendix p 2).
Estimates for decline in the normoglycaemic group—
used as a reference in the analyses—are listed in the 
appendix (p 10). Compared with normoglycaemic 
participants, those with known diabetes had a 45% 
faster decline in memory, a 29% faster decline in 
reasoning, and a 24% faster decline in global cognition; 
compared with the reference values, 10 year diﬀ erences 
in decline were –0·13 SD (–0·26 to –0·00) for memory; 
–0·10 SD (–0·19 to –0·01) for reasoning, and –0·11 SD 
(–0·21 to –0·02) for the global cognitive score in model 3 
(table 3). The signiﬁ cant decline in participants with 
known diabetes was equivalent to an age eﬀ ect of 
3·3 years for memory, 2·9 years for reasoning, and 
2·2 years for the global cognitive score. Participants 
with prediabetes and newly diagnosed diabetes did not 
show faster cognitive decline than those with 
normoglycaemia (table 3).
Sensitivity analyses showed that replacing hypertension 
with systolic and diastolic blood pressure as continuous 
variables in model 3 had little eﬀ ect on the estimates 
(appendix p 3); the results were much the same when 
participants who became diabetic during the period of 
cognitive testing were removed from the analysis 
(appendix p 4). Alternative classiﬁ cation of diabetes status 
(diagnosed 0–1·5 years ago vs more than 1·5 years ago) 
showed a faster cognitive decline in participants who had 
been diagnosed with diabetes more than 1·5 years ago 
than in those diagnosed more recently (appendix p 5). 
Use of time-dependent covariates in the longitudinal 
models showed signiﬁ cantly faster decline in reasoning 
and the global cognitive score in those with known 
diabetes (appendix p 6). Associations using imputed data 
showed stronger cross-sectional eﬀ ects (appendix p 7), 
but longitudinal results were similar to those from the 
main analysis (appendix p 8).
Mean HbA1c values were highest in participants with 
known diabetes (6·84%, SD 1·25) and lowest in those 
with normoglycaemia (5·40%, 0·40); newly diagnosed 
individuals (6·27%, 1·10) and participants with 
prediabetes (5·71%, 0·65) had intermediate values. In 
the fully adjusted analyses (model 3), a one percentage 
point increment in HbA1c was associated with a 
signiﬁ cantly faster decline in memory in participants 
with known diabetes, and a faster decline in reasoning in 
those with newly diagnosed (signiﬁ cant [p=0·028]) and 
known diabetes (approaching signiﬁ cance [p=0·052]; 
table 4). Using time-dependent covariates rather than 
those drawn from the 1997–99 assessment showed 
similar associations (appendix p 9).
Discussion
Our results from a large cohort of middle-aged adults 
show that participants with known diabetes—ie, those 
who had diabetes at the start of the study—had an 
increased rate of cognitive decline during the subsequent 
10 year period. The eﬀ ect of diabetes duration cannot be 
examined when all diabetes cases are analysed together, 
showing the pertinence of our research design. Faster 
cognitive decline in people with long-term diabetes, 
taking into account both cross-sectional and longitudinal 
analyses, corresponded to an age eﬀ ect of 7·5 years for 
reasoning and roughly 4·4 years for the global cognitive 
score. Cognitive decline in those with newly diagnosed 
diabetes and prediabetes was not diﬀ erent from that 
which occurred in normoglycaemic participants. We 
noted little attenuation of associations after taking into 
account potential confounding factors. Our results also 
show that in people with diabetes, those with poorer 
Model 1 Model 2 Model 3
Memory
Normoglycaemia ·· ·· ··
Prediabetes 0·02 (–0·05 to 0·09) 0·02 (–0·05 to 0·09) 0·02 (–0·05 to 0·09)
Newly diagnosed diabetes 0·07 (–0·09 to 0·22) 0·06 (–0·10 to 0·21) 0·06 (–0·10 to 0·21)
Known diabetes –0·13 (–0·26 to –0·01)* –0·13 (–0·26 to –0·00)† –0·13 (–0·26 to –0·00)‡
Reasoning
Normoglycaemia ·· ·· ··
Prediabetes –0·02 (–0·07 to 0·02) –0·03 (–0·07 to 0·02) –0·02 (–0·07 to 0·02)
Newly diagnosed diabetes –0·04 (–0·14 to 0·06) –0·04 (–0·15 to 0·06) –0·05 (–0·15 to 0·06)
Known diabetes –0·10 (–0·19 to –0·01)§ –0·10 (–0·18 to –0·01)¶ –0·10 (–0·19 to –0·01)||
Phonemic ﬂ uency
Normoglycaemia ·· ·· ··
Prediabetes 0·02 (–0·04 to 0·08) 0·02 (–0·04 to 0·07) 0·02 (–0·04 to 0·08)
Newly diagnosed diabetes –0·10 (–0·23 to 0·04) –0·10 (–0·24 to 0·03) –0·10 (–0·23 to 0·04)
Known diabetes –0·09 (–0·20 to 0·02) –0·08 (–0·20 to 0·03) –0·08 (–0·19 to 0·03)
Semantic ﬂ uency
Normoglycaemia ·· ·· ··
Prediabetes 0·00 (–0·05 to 0·06) 0·00 (–0·06 to 0·06) 0·00 (–0·05 to 0·06)
Newly diagnosed diabetes 0·03 (–0·10 to 0·16) 0·03 (–0·11 to 0·16) 0·02 (–0·11 to 0·16)
Known diabetes –0·06 (–0·17 to 0·05) –0·05 (–0·16 to 0·06) –0·05 (–0·16 to 0·06)
Global score
Normoglycaemia ·· ·· ··
Prediabetes –0·00 (–0·05 to 0·05) –0·00 (–0·05 to 0·05) –0·00 (–0·05 to 0·05)
Newly diagnosed diabetes –0·05 (–0·16 to 0·06) –0·05 (–0·16 to 0·06) –0·05 (–0·16 to 0·06)
Known diabetes –0·12 (–0·21 to –0·02)** –0·11 (–0·21 to – 0·02)†† –0·11 (–0·21 to –0·02)‡‡
Data are beta coeﬃ  cients (95% CI) based on standardised cognitive scores (mean=0, SD=1); –0·00 occurs because of  
rounding. Longitudinal analyses are based on data for cognitive function from 1997–99, 2002–04, 2007–09. p values 
for signiﬁ cant results (p<0·05) compared with reference group are indicated by footnotes. Model 1 is adjusted for age, 
sex, marital status, and education. Model 2 is adjusted for same parameters as model 1 plus health-related behaviours 
(smoking, alcohol, physical activity, and fruit and vegetable consumption). Model 3 is adjusted for same parameters as 
model 2 plus coronary heart disease, stroke, hypertension, respiratory disease, total cholesterol, obesity, use of 
antidepressants, and use of lipid-lowering drugs. n for normoglycaemia is 4703; n for prediabetes is 648; n for newly 
diagnosed diabetes is 115; and n for known diabetes is 187. *p=0·039. †p=0·042. ‡p=0·046. §p=0.028. ¶p=0·028. 
||p=0·026. **p=0·014. ††p=0·015. ‡‡p=0·014. 
Table 3: Estimated diﬀ erences in cognitive decline over 10 years, as a function of diabetes status in 
1997–99
See Online for appendix
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glycaemic control had faster cognitive decline. These 
ﬁ ndings suggest that duration of diabetes contributes to 
faster cognitive decline and that good glycaemic control 
could decrease this risk (panel).
Substantial evidence suggests that diabetes is a risk 
factor for cognitive decline and dementia.2,3 Some 
previous studies have suggested that the faster rate of 
cognitive decline aﬀ ects only elderly people with 
type 2 diabetes,23 with the hypothesis being that 
type 2 diabetes does not aﬀ ect cognition before old 
age.10,11 However, our results, from participants with 
median ages of 54, 60, and 65 years at the time of 
cognitive assessments, show that longer duration of 
diabetes is associated with more rapid cognitive decline. 
These ﬁ ndings are in line with previous results 
suggesting that midlife rather than late-life diabetes is a 
risk factor for dementia.24 These, along with our results, can 
be interpreted as showing that longer exposure to 
diabetes is harmful for cognition. A previous case-
control study25 in elderly people showed duration and 
severity of diabetes to be associated with mild cognitive 
impairment. Another study9 in adults aged 40–83 years, 
who were followed up for 12 years, showed that the 
extent of cognitive decline in individuals who developed 
diabetes during follow-up was between that of 
individuals without diabetes and those who had diabetes 
at baseline, albeit not signiﬁ cantly diﬀ erent from either 
group. Although our ﬁ nding that cognitive decline was 
not worse in those with prediabetes is in agreement with 
that of a previous study26 in elderly women, further 
research is needed since high glucose concentrations 
have been associated with an increased risk of dementia 
in people with glucose concentrations below the clinical 
threshold of manifest diabetes.27
All cognitive tests used in our analyses have been 
shown previously to be sensitive to age-related changes 
in cognition in midlife.18 In our study, known diabetes 
was associated with faster decline in memory, reasoning, 
and the global cognitive score. Although no signiﬁ cant 
cross-sectional eﬀ ects were evident for memory, the 
memory decline over 10 years was 45% faster in 
participants with known diabetes. Additionally, poor 
glycaemic control in diabetes was associated with a faster 
decline in memory and possibly in reasoning. Thus, 
various components of cognition seem to be aﬀ ected by 
type 2 diabetes, as evident in the robust eﬀ ects on the 
global cognitive score.
The precise mechanisms that underlie the association 
of diabetes with cognitive decline and dementia remain 
unclear. Vascular pathways are considered to be 
important.3 Diabetes is often associated with common 
cardiovascular risk factors such as dyslipidaemia, 
hypertension, and obesity.28 Complications related to 
microangiopathy have also been implicated.29 
Heterogeneous cerebral lesions, which cause cognitive 
dysfunction, are associated with longer diabetes duration; 
these lesions include ischaemic stroke, intracerebral 
haemorrhage, lacunar infarcts, white matter lesions, and 
cerebral atrophy.30
Our results emphasise the importance of duration of 
diabetes for cognitive ageing, and suggest that 
interventions that aim to prevent or delay diabetes onset 
might have implications for cognitive health. Lifestyle 
interventions have been shown to reduce the risk of 
progression from prediabetes to diabetes. A randomised 
trial31 of adults at high risk of type 2 diabetes showed that 
an intensive lifestyle modiﬁ cation programme reduced 
the risk of progression to diabetes by more than use of the 
antidiabetic drug metformin (58% [95 % CI 48–66] vs 31% 
[17–43]). Less clear is the eﬀ ect of tight glycaemic control 
on those with established disease. In the ACCORD MIND 
study,32 intervention to reduce HbA1c to less than 6% in 
people with type 2 diabetes was associated with reduced 
brain atrophy, although no eﬀ ect on cognitive decline was 
evident. By contrast, in the IDEATel trial,33 an HbA1c of 7% 
Model 1 Model 2 Model 3
Memory
Normoglycaemia –0·02 (–0·09 to 0·04) –0·03 (–0·09 to 0·03) –0·02 (–0·08 to 0·04)
Prediabetes –0·06 (–0·15 to 0·04) –0·05 (–0·15 to 0·04) –0·05 (–0·15 to 0·04)
Newly diagnosed diabetes –0·09 (–0·24 to 0·06) –0·09 (–0·23 to 0·06) –0·09 (–0·23 to 0·06)
Known diabetes –0·13 (–0·23 to –0·02)* –0·12 (–0·23 to –0·02)† –0·12 (–0·22 to –0·01)‡
Reasoning
Normoglycaemia –0·02 (–0·06 to 0·02) –0·01 (–0·05 to 0·03) –0·02 (–0·06 to 0·02)
Prediabetes –0·01 (–0·07 to 0·06) –0·00 (–0·07 to 0·06) 0·00 (–0·07 to 0·06)
Newly diagnosed diabetes –0·10 (–0·20 to –0·01)§ –0·11 (–0·20 to –0·01)¶ –0·11 (–0·20 to –0·01)||
Known diabetes –0·07 (–0·15 to –0·00)** –0·08 (–0·15 to –0·00)†† –0·07 (–0·15 to 0·00) 
Phonemic ﬂ uency
Normoglycaemia –0·03 (–0·08 to 0·03) –0·02 (–0·07 to 0·03) –0·01 (–0·07 to 0·04)
Prediabetes –0·07 (–0·15 to 0·01) –0·07 (–0·15 to 0·02) –0·06 (–0·14 to 0·02)
Newly diagnosed diabetes –0·06 (–0·19 to 0·06) –0·07 (–0·19 to 0·06) –0·07 (–0·19 to 0·06)
Known diabetes 0·01 (–0·09 to 0·11) 0·00 (–0·09 to 0·10) 0·01 (–0·09 to 0·10)
Semantic ﬂ uency
Normoglycaemia 0·01 (–0·04 to 0·06) 0·01 (–0·04 to 0·07) 0·01 (–0·04 to 0·06)
Prediabetes 0·01 (–0·07 to 0·09) 0·01 (–0·07 to 0·09) 0·01 (–0·07 to 0·09)
Newly diagnosed diabetes 0·02 (–0·10 to 0·15) 0·02 (–0·11 to 0·14) 0·02 (–0·11 to 0·14)
Known diabetes –0·02 (–0·11 to 0·08) –0·02 (–0·11 to 0·07) –0·02 (–0·12 to 0·07)
Global score
Normoglycaemia –0·01 (–0·06 to 0·03) –0·01 (–0·05 to 0·03) –0·01 (–0·05 to 0·03)
Prediabetes –0·05 (–0·11 to 0·02) –0·04 (–0·11 to 0·02) –0·04 (–0·11 to 0·03)
Newly diagnosed diabetes –0·08 (–0·18 to 0·02) –0·08 (–0·18 to 0·02) –0·08 (–0·18 to 0·02)
Known diabetes –0·06 (–0·14 to 0·02) –0·07 (–0·15 to 0·01) –0·06 (–0·14 to 0·01)
Data are beta coeﬃ  cients (95% CI) based on standardised cognitive scores (mean=0, SD=1); –0·00 occurs because of  
rounding. Data for cognitive function are from 1997–99, 2002–04, and 2007–09. p values for signiﬁ cant results 
(p<0·05) compared with reference group are indicated by footnotes. Model 1 is adjusted for age, sex, marital status, 
and education. Model 2 is adjusted for same parameters as model 1 and health-related behaviours (smoking, alcohol, 
physical activity, and fruit and vegetable consumption). Model 3 is adjusted for same parameters as model 2 and 
coronary heart disease, stroke, hypertension, respiratory disease, total cholesterol, obesity, use of antidepressants, and 
use of lipid-lowering drugs. n for normoglycaemia is 4336; n for prediabetes is 572; n for newly diagnosed diabetes is 
100; and n for known diabetes is 152.*p=0·020. †p=0·022. ‡=0·034. §p=0·034. ¶p=0·027. ||p=0·028. **p=0·049. 
††p=0·040.
Table 4: Association of glycaemic control (one percentage point increment in HbA1c) with estimated 
diﬀ erences in cognitive decline, by diabetes status in 1997–99
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or less was associated with slowed cognitive decline. 
Prevention of microvascular complications is highly 
dependent on glycaemic control in adults with 
type 2 diabetes, but no eﬀ ect on macrovascular disease or 
mortality was seen in elderly people with longstanding 
type 2 diabetes.34 Cumulative glycaemic exposure (ie, 
severity and duration of hyperglycaemia) is important for 
microvascular complications,35 and increases the risk of 
more rapid cognitive decline. 
The strengths of this analysis from the Whitehall II 
study are the prospective cohort and the fairly young 
population—75% of participants were younger than 
71 years at the last cognitive assessment. The repeated 
standardised screening for diabetes before the start of 
cognitive follow-up allowed us to minimise reverse 
causation biases. Alternative classiﬁ cation of duration of 
diabetes gave similar results. We also took into account a 
range of potential confounders of the association 
between diabetes and cognition. The major limitation of 
this study is the issue of generalisability, since the data 
are for an occupational cohort and the participants are 
likely to be healthier than the general population. Finally, 
because of the small numbers of non-white participants, 
we could not examine the duration-of-diabetes hypothesis 
in this group, so the extent to which the results apply to 
non-white populations is unclear.
Our results support the hypothesis that the risk of 
accelerated cognitive decline in people with diabetes 
depends on how long an individual has had the disease 
and on the extent to which they can achieve normal 
carbohydrate metabolism. Further research is needed to 
determine whether improving management of 
type 2 diabetes also reduces the risk of dementia.
Panel: Research in context
Systematic review
We searched PubMed for research articles and reviews in 
English published up to Sept 30, 2013. We used the search 
terms “type 2 diabetes” and “cognitive decline” in the title or 
abstract. We also searched the reference lists of retrieved 
articles and identiﬁ ed additional relevant publications on the 
link between diabetes, cognitive deﬁ cits, and dementia 
through manual search. We found consistent evidence that the 
risk of dementia is increased in people with type 2 diabetes.2–4 
However, previous studies did not closely examine the relation 
between diabetes duration and cognitive decline, or the eﬀ ect 
of glycaemic control. 
Interpretation
Our results show that a longer diabetes duration is associated 
with faster cognitive decline. Additionally, for people with 
diabetes, poor glycaemic control was associated with faster 
cognitive decline. Thus, interventions that delay diabetes 
onset, as well as tight glycaemic control in those with 
established disease, might help to prevent some of the 
deleterious eﬀ ects of type 2 diabetes on cognitive ageing. 
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